These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 30455077)

  • 1. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
    Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
    Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
    Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
    Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.
    Constantin JM; Jabaudon M; Lefrant JY; Jaber S; Quenot JP; Langeron O; Ferrandière M; Grelon F; Seguin P; Ichai C; Veber B; Souweine B; Uberti T; Lasocki S; Legay F; Leone M; Eisenmann N; Dahyot-Fizelier C; Dupont H; Asehnoune K; Sossou A; Chanques G; Muller L; Bazin JE; Monsel A; Borao L; Garcier JM; Rouby JJ; Pereira B; Futier E;
    Lancet Respir Med; 2019 Oct; 7(10):870-880. PubMed ID: 31399381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
    Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
    Villar J; Ferrando C; Martínez D; Ambrós A; Muñoz T; Soler JA; Aguilar G; Alba F; González-Higueras E; Conesa LA; Martín-Rodríguez C; Díaz-Domínguez FJ; Serna-Grande P; Rivas R; Ferreres J; Belda J; Capilla L; Tallet A; Añón JM; Fernández RL; González-Martín JM;
    Lancet Respir Med; 2020 Mar; 8(3):267-276. PubMed ID: 32043986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
    Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
    Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.
    Gates S; Perkins GD; Lamb SE; Kelly C; Thickett DR; Young JD; McAuley DF; Snaith C; McCabe C; Hulme CT; Gao Smith F
    Health Technol Assess; 2013 Sep; 17(38):v-vi, 1-87. PubMed ID: 24028755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
    Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
    Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
    Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT;
    Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of acute respiratory distress syndrome (ARDS) in elderly patients.
    Eachempati SR; Hydo LJ; Shou J; Barie PS
    J Trauma; 2007 Aug; 63(2):344-50. PubMed ID: 17693834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
    Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
    Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
    McAuley DF; Cross LM; Hamid U; Gardner E; Elborn JS; Cullen KM; Dushianthan A; Grocott MP; Matthay MA; O'Kane CM
    Lancet Respir Med; 2017 Jun; 5(6):484-491. PubMed ID: 28526233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS.
    Wick KD; Leligdowicz A; Zhuo H; Ware LB; Matthay MA
    JCI Insight; 2021 Jun; 6(12):. PubMed ID: 33974564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
    Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
    Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
    Needham CJ; Brindley PG
    Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.
    Pochon C; Laroye C; Kimmoun A; Reppel L; Dhuyser A; Rousseau H; Gauthier M; Petitpain N; Chabot JF; Valentin S; de Carvalho Bittencourt M; Peres M; Aarnink A; Decot V; Bensoussan D; Gibot S
    Front Med (Lausanne); 2023; 10():1224865. PubMed ID: 37706025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.